Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Steven G. Waguespack(The University of Texas MD Anderson Cancer Center), Camilo Jiménez(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Sireesha Yedururi(The University of Texas MD Anderson Cancer Center), Steven I. Sherman(The University of Texas MD Anderson Cancer Center), Mark Zafereo(The University of Texas MD Anderson Cancer Center)
Cited by 9
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1
|The Journal of Clinical Endocrinology & Metabolism|1999|564
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551